Moderna and its partner Merck announced research results on Wednesday: An experimental mRNA vaccine can prevent cancer recurrence or spread in patients with high-risk melanoma, offering hope for a new life-extending therapy for thousands of people diagnosed annually with this deadly form of skin cancer. The vaccine targets patients who have already undergone surgery to remove melanoma, aiming to reduce the risk of cancer recurrence.